biote (NASDAQ:BTMD) Stock Price Up 0.5% - What's Next?

biote Corp. (NASDAQ:BTMD - Get Free Report) shot up 0.5% on Friday . The stock traded as high as $4.22 and last traded at $4.21. 25,438 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 174,350 shares. The stock had previously closed at $4.19.

Wall Street Analyst Weigh In

Separately, Craig Hallum reduced their price target on biote from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Thursday, March 13th.

biote Price Performance

The company has a market cap of $222.12 million, a P/E ratio of 6.66 and a beta of 1.21. The company has a 50 day moving average of $3.85 and a 200-day moving average of $4.32.

biote (NASDAQ:BTMD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. The company had revenue of $48.99 million during the quarter, compared to analyst estimates of $47.25 million. biote had a negative return on equity of 19.44% and a net margin of 10.93%. Research analysts anticipate that biote Corp. will post 0.75 EPS for the current year.

Insider Transactions at biote

In other biote news, major shareholder Guines Llc acquired 436,037 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was bought at an average price of $3.26 per share, with a total value of $1,421,480.62. Following the completion of the purchase, the insider owned 4,611,071 shares of the company's stock, valued at approximately $15,032,091.46. This represents a 10.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders acquired a total of 467,177 shares of company stock worth $1,522,692 over the last three months. 24.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On biote

Several large investors have recently added to or reduced their stakes in BTMD. Sei Investments Co. lifted its stake in biote by 56.4% during the fourth quarter. Sei Investments Co. now owns 18,321 shares of the company's stock worth $113,000 after purchasing an additional 6,605 shares during the last quarter. Renaissance Technologies LLC lifted its stake in biote by 9.8% during the fourth quarter. Renaissance Technologies LLC now owns 178,994 shares of the company's stock worth $1,106,000 after purchasing an additional 16,017 shares during the last quarter. Millennium Management LLC bought a new stake in biote during the fourth quarter worth about $414,000. Squarepoint Ops LLC bought a new stake in biote during the fourth quarter worth about $115,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in biote during the fourth quarter worth about $67,000. Institutional investors own 21.68% of the company's stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.